Biperiden Trial for Epilepsy Prevention

Recruiting now · Phase 3 · Has a placebo group

Conditions studied: Brain Injury Traumatic Moderate, Brain Injury Traumatic Severe, Post Traumatic Epilepsy

In brief

One of the most important neurological consequences following Traumatic Brain Injury (TBI) is the development of post traumatic epilepsy (PTE). Nevertheless, there is still no effective therapeutic intervention to reduce the occurrence of PTE. In previous studies with animals models of epilepsy, the biperiden decreased the incidence and intensity of spontaneous epileptic seizures besides delaying their appearance. The aim of this study is the evaluation of biperiden as antiepileptogenic drug to prevent PTE and also the determination of side effects, evaluating its cost-effectiveness in patients with moderate and severe TBI.

Key facts

Study ID
NCT04945213
Run by
Hospital Sirio-Libanes
People needed
312
Starts
2023-01-10
Expected to finish
2026-12-20
Last updated by the study team
2024-03-26

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.